Saturday 17 October 2026
Export NNOX’s income statement to Excel — free account
Nano-X Imaging Ltd.
NNOX Healthcare Medical Devices
Nano-X Imaging Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.7%, EPS fell 243.5%, free cash flow fell 21.4% and total debt fell 12.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.45
0.04
−8.16%
Follow NNOX
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | 6 | 4 | 3 |
P/E ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | 0.00 | 43.42 | 36.76 | 37.44 | 13.93 |
Altman Z-Score |
— | — | — | — | 4.94 | 3.55 | 6.76 | 9.18 | (0.16) |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | 2.63 | 1.14 | 4.37 | 3.91 | (3.70) |
P/FCF ratio |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | (36.31) | (25.46) | (29.10) | (40.11) | (17.42) |
P/B ratio |
— | — | — | — | 2.40 | 1.72 | 1.86 | 2.23 | 1.30 |
Price to Tangible BV |
— | — | — | — | 5.31 | 3.16 | 3.17 | 3.55 | 2.28 |
EV/Sales |
— | — | — | — | 0.00 | 34.86 | 29.13 | 32.89 | 10.66 |
EV/EBITDA |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | (16.19) | (6.89) | (6.44) | (10.14) | (3.40) |
EV/FCF |
— | — | — | — | (10.07) | (5.91) | (6.00) | (9.43) | (3.08) |
Quick Ratio |
— | 0.00 | 0.40 | 47.65 | 1.70 | 3.13 | 5.41 | 4.26 | 3.03 |
Current Ratio |
— | 0.21 | 0.48 | 49.06 | 1.80 | 3.29 | 5.71 | 5.63 | 3.96 |
Net Debt/EBITDA |
— | 0.00 | 0.34 | 4.85 | 1.43 | 1.36 | 1.85 | 1.21 | 0.69 |
Debt/Assets |
0.00% | 0.00% | 4.43% | 0.61% | 1.09% | 1.66% | 1.60% | 1.46% | 1.93% |
Debt/Equity |
— | 0.00 | (0.06) | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.04 | 0.05 | 0.07 |
Operating CF/Net income |
— | 1.92 | 0.24 | 0.49 | 0.62 | 0.38 | 0.74 | 0.68 | 0.54 |
Capex/Depreciation |
— | (2.09) | (2.36) | (67.00) | (11.16) | (0.11) | (0.17) | (0.24) | (0.36) |
| — | 25.18% | 297.63% | (39.48%) | (23.64%) | (44.51%) | (29.49%) | (27.83%) | (45.62%) | |
| — | (205.82%) | (328.76%) | (35.33%) | (20.62%) | (36.70%) | (25.72%) | (24.97%) | (40.31%) | |
ROIC |
— | 0.00% | 0.00% | (146.64%) | (18.55%) | (51.35%) | (33.56%) | (26.37%) | (52.17%) |
Return on Tangible Assets |
— | 29.90% | 216.97% | (19.11%) | (77.69%) | (112.20%) | (52.64%) | (48.62%) | (94.27%) |
Average Days of Receivables |
— | — | — | — | 294.18 | 41.57 | 54.69 | 58.39 | 56.43 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 1,313.04% | 309.01% | 262.99% | 178.87% | 147.73% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 3,201.07% | 531.94% | 287.13% | 229.24% | 209.29% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.44 | 0.39 | 0.37 | 0.33 | 0.37 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 1,442.18% | 217.10% | 69.04% | 64.35% | 32.18% |
Graham Net Nets |
— | — | — | — | 0.03 | 0.12 | 0.18 | 0.14 | 0.24 |
Graham Number |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | (8.73%) | (28.33%) | (16.56%) | (12.50%) | (41.17%) |
Free Cash Flow Yield |
— | — | — | — | (8.73%) | (13.57%) | (13.20%) | (9.32%) | (24.81%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.03 | 0.16 | 0.18 | 0.19 | 0.20 |
Operating CF per Share |
— | (0.18) | (0.22) | (0.60) | (0.79) | (0.83) | (0.79) | (0.62) | (0.63) |
Capex per Share |
— | 0.00 | 0.00 | (0.39) | (0.48) | (0.14) | (0.06) | (0.05) | (0.06) |
Free Cash Flow per Share |
— | (0.18) | (0.22) | (0.99) | (1.27) | (0.97) | (0.85) | (0.67) | (0.69) |
Cash per Share |
— | 0.00 | 0.32 | 5.99 | 1.84 | 1.49 | 1.46 | 0.98 | 0.76 |
Shareholders Equity per Share |
— | (0.31) | (0.35) | 6.47 | 6.06 | 4.15 | 3.47 | 3.22 | 2.16 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.31) | (0.35) | 6.47 | 6.06 | 4.15 | 3.47 | 3.22 | 2.16 |
Free Cash Flow |
— | (3.74) | (5.65) | (35.42) | (61.22) | (50.56) | (48.08) | (39.36) | (45.00) |
Working Capital |
— | (6.54) | (10.63) | 215.31 | 42.11 | 57.39 | 73.11 | 64.71 | 49.91 |
Capital Expenditures |
— | (0.07) | (0.12) | (13.94) | (23.16) | (7.17) | (3.30) | (2.77) | (4.21) |
Net Current Asset Value |
— | (6.54) | (11.01) | 214.39 | 23.84 | 45.21 | 65.50 | 57.80 | 44.36 |
EV/EBIT |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 17.76 | 0.84 | 0.33 | 0.25 | 0.32 |
Price to Operating Income |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.22 | 0.23 | 0.01 | 0.06 | 1.46 | 0.47 | 0.25 | 0.40 |
Cash ROIC |
— | 58.69% | 3,138.33% | (7.95%) | (15.91%) | (16.94%) | (17.08%) | (15.75%) | (23.44%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 8.46 | 8.05 | 6.86 | 6.82 |
Accounts Payable Turnover |
— | 0.13 | 0.19 | 0.46 | 1.58 | 4.58 | 4.77 | 7.94 | 10.13 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.38 | 11.31 |
Average Days of Payables |
— | 855.14 | 3,271.23 | 763.34 | 406.22 | 85.45 | 73.08 | 36.83 | 40.81 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 52.13 | 24.89 | 43.42 |
Average Receivables |
— | — | — | — | — | 1.01 | 1.23 | 1.64 | 1.91 |
Average Payables |
— | 0.28 | 0.28 | 0.46 | 1.78 | 3.38 | 3.46 | 2.76 | 2.55 |
Average Inventory |
— | — | — | — | — | — | — | 1.92 | 2.28 |
Average Assets |
— | 0.93 | 6.86 | 124.01 | 299.66 | 308.55 | 236.29 | 214.33 | 186.08 |
Average Common Equity |
— | (7.58) | (7.58) | 110.98 | 261.45 | 254.41 | 206.10 | 192.32 | 164.43 |
Columns are period end dates